2080 Century Park East
About EpicGeneticsEpicGenetics, Inc. is a privately held biomedical company based in Los Angeles, California, that developed and manufactures the FM/a® Test. EpicGenetics is dedicated to improving the diagnosis and treatment of fibromyalgia by offering the first conclusive diagnostic test for fibromyalgia, and by investing in and developing further comprehensive clinical studies at leading medical research centers.
CEO: Bruce Gillis
5 articles with EpicGenetics
University of Illinois College of Medicine and EpicGenetics Deploy Test to Determine Patients Most Likely to Avoid Potentially Fatal Cytokine Storms that May Trigger the Most Severe Cases of COVID-19
EpicGenetics to offer a no-fee immune system COVID-19 FDA-authorized antibody test with every FM/a® Test
EpicGenetics, the biomedical company that developed and offers the FM/a Test, the FDA-compliant diagnostic blood test that identifies the immune system biomarkers of fibromyalgia, today announced a 50 percent growth in applications for the test.
After analyzing thousands of patients, EpicGenetics today announced that its data shows that 80 percent of young people (under 19 years of age) who were tested for fibromyalgia were previously misdiagnosed with attention deficit hyperactivity disorder (ADHD).
EpicGenetics and Massachusetts General Hospital (MGH) are launching a Phase II clinical trial to test a tuberculosis vaccine, BCG, as a potential treatment for fibromyalgia.